Early Detection of Perinatal Depression With Wearable Technology (BLUESMAPPED)
Biometrics in Longitudinal Uptake for Early Monitoring and Assessing Perinatal Patterns of Emotions in Depression
The goal of this feasibility study is to learn whether wearable devices and self-report surveys can help researchers better understand changes in mood during pregnancy and after birth in young pregnant individuals with a history of major depressive disorder. The study will also examine whether this type of monitoring is practical and acceptable for participants and clinicians. The main questions it aims to answer are:
- Can researchers successfully collect wearable and survey data throughout late pregnancy and the first 3 months after birth?
- Do participants and clinicians find wearable-based monitoring easy to use and helpful?
- Are changes in sleep, heart rate, activity, and other wearable data linked to mood changes during the perinatal period?
Researchers will compare 2 wearable devices, the Oura Ring and EmbracePlus, to see which device provides more complete and usable data.
Participants will:
- Wear either the Oura Ring or EmbracePlus device every day from the third trimester of pregnancy until 3 months after birth
- Complete short daily and biweekly questionnaires about mood and wellbeing
- Allow the wearable device to collect information such as sleep, heart rate, heart rate variability, and physical activity
The study will include 10 participants. Researchers will measure feasibility by looking at how many participants join the study and how much study data is completed. The study team hopes at least 70% of scheduled study activities data will be collected.
Researchers will also interview 5 participants and 4 reproductive psychiatry clinicians about their experiences using wearable monitoring. These interviews will explore ease of use, usefulness in clinical care, and how wearable data may fit into electronic medical records.
This study may help researchers develop future tools that can predict the risk of perinatal depression earlier and support more personalized care during pregnancy and after birth.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Blanca Bolea-Alamanac, MD PhD
- 电话号码:4221 416-323-6400
- 邮箱:blanca.boleaalamanac@wchospital.ca
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5S 1B2
- Women's College Hospital
-
接触:
- Blanca M Bolea, MD PhD
- 电话号码:4221 416-323-6400
- 邮箱:Blanca.BoleaAlamanac@wchospital.ca
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥ 16 years
- Pregnant, 13-27 weeks gestation at enrollment
- Previous diagnosis of major depressive disorder (MDD), confirmed by Mini International Neuropsychiatric Interview (MINI) (not necessarily perinatal onset)
- Currently in remission (EPDS score < 9)
- Access to a smartphone and internet, or willingness to use a study-provided device
Exclusion Criteria:
- Active alcohol or substance use disorder within the past 12 months
- Active suicidal ideation
- History of bipolar disorder or primary psychotic disorder
- Physical condition preventing use of Oura Ring or EmbracePlus (expected to be rare)
学习计划
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Oura Ring
Participants randomized to this arm will wear the Oura Ring continuously from the third trimester of pregnancy through three months postpartum.
The device will collect sleep, activity, heart rate, and heart rate variability data passively, alongside daily and biweekly self-report measures.
|
A lightweight titanium ring worn continuously on the index finger that passively collects sleep, physical activity, heart rate, and heart rate variability data via infrared optical sensors and a 3D accelerometer.
Worn throughout the third trimester of pregnancy and three months postpartum to monitor physiological parameters associated with perinatal depression risk.
|
|
有源比较器:EmbracePlus
Participants randomized to this arm will wear the EmbracePlus smartwatch continuously from the third trimester of pregnancy through three months postpartum.
The device will collect sleep, activity, heart rate, heart rate variability, and electrodermal activity data passively, alongside daily and biweekly self-report measures.
|
A medical-grade waterproof smartwatch worn continuously on the wrist that passively collects sleep, physical activity, heart rate, heart rate variability, and electrodermal activity data via photoplethysmography and ventral electrodermal sensors.
Worn throughout the third trimester of pregnancy and three months postpartum to monitor physiological parameters associated with perinatal depression risk.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Wearable device adherence completion rate
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Feasibility of continuous wearable device data collection will be assessed by the proportion of scheduled data points completed during continuous daily wear.
Wearable use profiles will be categorized as low, moderate, or high based on continuous daily wear without interruptions of more than 3 hours.
Feasibility will be established if ≥ 70% of scheduled data points are completed across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Daily Visual Analogue Scale mood entry completion rate
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Feasibility of daily mood self-reporting will be assessed by the proportion of scheduled Visual Analogue Scale mood entries completed by participants.
The Visual Analogue Scale is a 100-point scale (range: 0-100), where higher scores indicate better mood.
Feasibility will be established if ≥ 70% of scheduled entries are completed across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Edinburgh Postnatal Depression Scale completion rate
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Feasibility of biweekly depression screening will be assessed by the proportion of scheduled Edinburgh Postnatal Depression Scale surveys completed.
The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item questionnaire (range: 0-30), where higher scores indicate greater severity of depressive symptoms.
Feasibility will be established if ≥ 70% of scheduled surveys are completed across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Generalized Anxiety Disorder-7 completion rate
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Feasibility of biweekly anxiety screening will be assessed by the proportion of scheduled Generalized Anxiety Disorder-7 surveys completed.
The Generalized Anxiety Disorder-7 is a 7-item questionnaire (range: 0-21), where higher scores indicate greater severity of anxiety symptoms.
Feasibility will be established if ≥ 70% of scheduled surveys are completed across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Wearable device acceptability among participants (quantitative)
大体时间:At 3 months postpartum (end of study)
|
Acceptability of the wearable device will be assessed through a questionnaire administered to participants at study completion.
Questions will evaluate comfort, ease of use, perceived burden, satisfaction with the device, and willingness to continue use in a larger study.
All questions will be rated from 0-5 (0 being strongly disagree, 3 being neutral, 5 being strongly agree)
|
At 3 months postpartum (end of study)
|
|
Wearable device acceptability among participants (qualitative)
大体时间:At 3 months postpartum (end of study)
|
Acceptability the wearable device will be assessed through semi-structured interviews administered to participants at study completion.
Questions will evaluate comfort, ease of use, perceived burden, satisfaction with the device, and willingness to continue use in a larger study using thematic analysis.
|
At 3 months postpartum (end of study)
|
|
Wearable device usability among participants
大体时间:At 3 months postpartum (end of study)
|
Usability of the wearable device will be assessed through the System Usability Scale (SUS) administered to participants at study completion.
Questions will evaluate comfort and ease of use the device on a 5 point scale (0- strongly disagree, 3- neutral, 5-strongly agree).
|
At 3 months postpartum (end of study)
|
|
Wearable device acceptability and integration from the clinician perspective
大体时间:Throughout the study period, up to 3 months postpartum
|
Clinician acceptability will be assessed through questionnaires and interviews conducted during the study period, evaluating views on wearable technology, potential integration of device-derived data into electronic medical records, and feasibility of incorporating wearable monitoring into routine perinatal care workflows.
(Usability of the device will be rated on a likert scale: Strongly disagree (1) to Strongly agree (5))
|
Throughout the study period, up to 3 months postpartum
|
|
Participant recruitment
大体时间:up to 56 weeks from the recruitment start date
|
Recruitment feasibility will be defined as successful enrollment of 10 eligible pregnant participants.
|
up to 56 weeks from the recruitment start date
|
|
Participant retention
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Retention will be considered successful if ≥ 80% of enrolled participants complete follow-up through 3 months postpartum.
Reasons for dropout or discontinuation will be recorded.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation between sleep duration and depression symptom severity
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between sleep duration (hours/night, recorded by wearable device) and depression symptom severity (total score on the Edinburgh Postnatal Depression Scale, 0-30).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between physical activity and depression symptom severity
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between physical activity (steps/day, recorded by wearable device) and depression symptom severity (total score on the Edinburgh Postnatal Depression Scale, 0-30).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between heart rate and depression symptom severity
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between resting heart rate (beats per minute, recorded by wearable device) and depression symptom severity (total score on the Edinburgh Postnatal Depression Scale, 0-30).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between heart rate variability and depression symptom severity
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between heart rate variability (RMSSD, ms, recorded by wearable device) and depression symptom severity (total score on the Edinburgh Postnatal Depression Scale, 0-30).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between physical activity and daily mood
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between physical activity (steps/day, recorded by wearable device) and daily mood (score on a visual analogue scale, 0-100).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between heart rate and daily mood
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between resting heart rate (beats per minute, recorded by wearable device) and daily mood (score on a visual analogue scale, 0-100).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Correlation between heart rate variability and daily mood
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Correlation between heart rate variability (RMSSD, ms, recorded by wearable device) and daily mood (score on a visual analogue scale, 0-100).
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Comparison of data completeness between wearable devices
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Comparison of data completeness (% of expected data points successfully recorded) between the two wearable devices across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
|
Comparison of data quality between wearable devices
大体时间:From enrollment (13-27 weeks gestation) through 3 months postpartum
|
Comparison of data quality (% of recorded data points meeting acceptable signal quality thresholds) between the two wearable devices across the study period.
|
From enrollment (13-27 weeks gestation) through 3 months postpartum
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2025-0085-E
- 12345 (其他赠款/资助编号:Reasons for Hope Fund in Prevention and Early Detection of Mental Illness)
- 39923 (其他赠款/资助编号:Canada Foundation for Innovation)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.